The pharma company began funding the consortium in 2012 and will be involved with it for at least another five years.
The consortium will analyze data from patients and mouse models in the first year as part of efforts to find ways of detecting tumors earlier.
The initial phase of GENIE, which stands for Genomics, Evidence, Neoplasia, Information, Exchange, involves seven founding members and two informatics partners.
The Personalized Reproductive Medicine Initiative will investigate how an individual's genetic signature and personalized metrics affect overall fertility.
The consortium, a group formed by a number of participants in Oxford Nanopore's MinIon early-access program (MAP), plans to conduct a series of projects.
The database of genotype, phenotype, and clinical data from multi-drug resistant TB cases may support improved diagnostic development and clinical decision making.
Illumina is the latest to join the consortium, which is focused on personalizing cancer care.
The effort brings together gene banks, researchers, plant breeders, and big data experts, all of whom will use genomics to unlock crop diversity.
The gene fusion assay maker is the sixth member to join the consortium, which also includes Illumina and several pharmaceutical companies.
The oncology data warehouse started by the Moffitt Cancer Center and Ohio State University Comprehensive Cancer Center now has nine members.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.